Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus

Front Immunol. 2023 Jan 4:13:1066268. doi: 10.3389/fimmu.2022.1066268. eCollection 2022.

Abstract

Introduction: The erythrocyte membranes used in nanovaccines include high membrane stability, long circulation life, adaptability and extremely good bio compatibility. Nanoparticles encapsulated by erythrocyte membranes are widely used as ideal drug delivery vehicles because of their high drug loading, long circulation time, and excellent biocompatibility. The mannose modification of delivery materials can help target mannose receptors (MRs) to deliver antigens to antigen-presenting cells (APCs).

Methods: In this study, the antigen gene gp90 of avian reticuloendotheliosis virus (REV) was encapsulated with carboxymethyl chitosan (CS) to obtain CSgp90 nanoparticles, which were coated with mannose-modied fowl erythrocyte membranes to yield CS-gp90@M-M nanoparticles. The physicochemical characterization and immune response of the CS-gp90@M-M nanoparticles were investigated in vitro and in vivo.

Results: CS-gp90@M-M nanoparticles were rapidly phagocytized in vitro by macrophages to induce the production of cytokines and nitric oxide. In vivo, CS-gp90@M-M nanoparticles increased cytokine levels, the CD4+/8+ ratio, REV-specific antibodies in the peripheral blood of chicks, and the mRNA levels of immune-related genes in the spleen and bursa of immunized chicks. CS-gp90@M-M nanoparticles could be targeted to lymphoid organs to prolong the retention time of the nanoparticles at the injection site and lymphatic organs, leading to a strong, sustained immune response. Moreover, the CS-gp90@M-M nano-vaccine showed a lasting immunoprotective effect and improved the body weight of chicks after the challenge.

Conclusion: Overall, CS-gp90@M-M nanoparticles can be used in vaccine designs as an effective delivery carrier with immune response-enhancing effects.

Keywords: chitosan; delivery system; erythrocyte membrane; mannose modification; reticuloendothelial virus bionic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral
  • Chickens
  • Erythrocyte Membrane
  • Hyperplasia
  • Mannose
  • Nanoparticles* / chemistry
  • Vaccines, DNA*

Substances

  • Vaccines, DNA
  • Mannose
  • Antibodies, Viral

Grants and funding

The project was supported by the National Natural Science Foundation of China (Project No. 31872511) and in part by the Applied Basic Research Program of Sichuan Province (Project No. 2021YJ0289) and in part by Initial Foundation of Scientific Research for the Introduction of Talents (Project No. RQD2021075).